1. Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
   Coralie Reger de Moura et al, 2020, Frontiers in Oncology CrossRef
2. Discoidin Domain Receptor 1, a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma
   Linghong Wu et al, 2022, International Journal of General Medicine CrossRef
3. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
   William H. Chappell et al, 2020, Aging CrossRef
4. Network controllability solutions for computational drug repurposing using genetic algorithms
   Victor-Bogdan Popescu et al, 2022, Scientific Reports CrossRef
5. Recent Advances in the Role of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast and Ovarian Cancer
   Li Chen et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
6. Tumor DDR1 deficiency reduces liver metastasis by colon carcinoma and impairs stromal reaction
   Irene Romayor et al, 2021, American Journal of Physiology-Gastrointestinal and Liver Physiology CrossRef
7. Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib
   Myles Vigoda et al, 2022, Cancer Biology & Therapy CrossRef
8. Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors
   Girieca Lorusso et al, 2020, Frontiers in Oncology CrossRef
9. Evaluation of t-DARPP Expression Alteration in Association with DDR1 Expression in Non-Small Cell Lung Cancer
   Zahra Damavandi et al, 2024, Iranian Biomedical Journal CrossRef
10. Oral Administration of Prunella vulgaris L Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects
    Jixue Zhao et al, 2018, Frontiers in Pharmacology CrossRef